NCT04283461View on ClinicalTrials.gov

Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)

PHASE1CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

March 16, 2020

Primary Completion Date

April 26, 2022

Study Completion Date

April 26, 2022

Conditions
COVID-19COVID-19 Immunisation
Interventions
BIOLOGICAL

mRNA-1273

Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike protein 2019-nCoV. mRNA-1273 consists of an mRNA Drug Substance that is manufactured into LNPs composed of the proprietary ionizable lipid, SM-102, and 3 commercially available lipids, cholesterol, DSPC, and PEG2000 DMG.

Trial Locations (3)

20892

National Institutes of Health - Clinical Center - Vaccine Research Center Clinical Trials Program, Bethesda

30030-1705

The Hope Clinic of Emory University, Decatur

98101-1466

Kaiser Permanente Washington Health Research Institute, Seattle

All Listed Sponsors
collaborator

ModernaTX, Inc.

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT04283461 - Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19) | Biotech Hunter | Biotech Hunter